Third-Party Clinical Study Documents Industry-Leading Long-Term Safety Record and Patient Satisfaction for GC Aesthetics Breast Implants

The clinical data in the study is based upon an average of 17 years of patient follow-up. This is unprecedented in the breast implant industry and confirms GC Aesthetics’ unparalleled safety record, built upon its 40-years of innovation and collaboration with surgeons worldwide.

DUBLIN, Ireland: GC Aesthetics, Ltd. (GCA), a privately held medical technology company providing aesthetic and reconstructive solutions for global healthcare markets, has announced the results of an independent clinical study that documented industry-leading safety and patient satisfaction results for GCA’s breast implants, based upon an average of 17 years of patient follow-up.

Breast implant safety is a key business driver and corporate focus for GC Aesthetics, especially over the long-term. Short-term, or limited, data can provide misleading information to surgeons and patients since actual complication rates can be underestimated or prematurely judged over shorter terms.

While there are a few other smooth breast implants offered in the market, PERLE™ is proving itself to be superior in features and performance. These features include its (R)evolutionary BioQ™-surface, exclusive Emunomic™ Breast Tissue Dynamic Gel, Enhanced GCA Ultra-link shell, and Advanced RRE patch. PERLE™ represents the best in smooth opaque breast implants.

Based on its key features, highly respected surgeons all over Europe are embracing PERLE™ and are quickly positioning the product to be the preferred type of breast implant surface. As Taimur Shoaib, founder and senior plastic surgeon at the prestigious La Belle Forme commented: “I’m always looking around to use what I think are the best implants available at the time for my patients. I think PERLE™ breast implants are the world’s best.”

GCA already had a very positive and compelling 10-year clinical study, published in 2018, involving over 500 women who received its implants (Duteille et al. 2018). The new study was lead by Prof van der Lei in The Netherlands (Kooiman et al. 2021). It analyzed the very long-term patient satisfaction and exceptionally low revision rate for GCA round micro-textured breast implants. It also reported no ALCL (Anaplastic Large Cell Lymphoma) cases from GCA implants.

In breast augmentation surgery with implants, it has been seen that the cumulative risk of complications, such as capsular contracture, increases over time. Having significant long-term clinical data regarding the safety of GCA’s breast implants adds important information to the scientific literature, and it also provides powerful evidence of the long-term safety of GC Aesthetics’ breast implants.

“The proven and long-standing safety record of GCA’s products has enabled us to build market-leading positions in key markets around the world, and to earn the confidence of surgeons and patients across the globe. Results like this have allowed GCA to ensure that our products are safe and highly effective in achieving the needs of the industry” said Carlos Reis Pinto, CEO of GC Aesthetics. “This clinical study by Prof. Dr. Berend van der Lei, provides evidence of what we have professed for years: long-term data matters, and great long-term results for patients matters even more. Most breast implants in the market are not backed by this kind of data.”

The new clinical study results are once again demonstrating what makes GC Aesthetics an industry leader, as the company continues to expand its market reach and its innovative product portfolio, for both aesthetic and reconstruction breast surgeries. Its products are backed by decades of research, addressing key market needs. GCA has aggressive growth planned for 2022, fueled by its innovative product launches, and its further expansion in key markets, capitalizing on its success in 2021.

About GC Aesthetics

GC Aesthetics is a long-established global medical technology company that develops, manufactures in-house, and markets a comprehensive range of proprietary aesthetic and reconstructive products.

Throughout its 40 years of operation, GCA has been dedicated to advancing the science of medical aesthetics. GCA is proud to have sold more than 3 million implants across 70 countries, with its products supported by long-term 10-year clinical data that clearly demonstrates the compelling safety and clinical effectiveness of its products.

GC Aesthetics®, A Confident Choice for Life™

We also think you’ll like…

GC Aesthetics® to participate in the 54th SECPRE National Congress

GC Aesthetics® to participate in the 54th SECPRE National Congress

GC Aesthetics® will participate in the 54th edition of the SECPRE National Congress , which will feature round tables, surgeries with live comments and keynote lectures. The event will be held from May 25-27th at the Palacio de Congresos y Exposisiones de Galicia,...

GCA® proud sponsors on the 32nd EURAPS Annual meeting

GCA® proud sponsors on the 32nd EURAPS Annual meeting

GC Aesthetics® is delighted to participate as Platinum Sponsor at the 2022 EURAPS Annual Meeting that will take place from May 26th to 28th in Naples at the at Stazione Marittima Congress Centre, located in the city center. Established in 1989, some of the main...